ResMed is leveraging the popularity of Ozempic-style weight loss drugs to enhance screenings for sleep apnea, reporting ...

ResMed dominates the global sleep apnea device market, boasting a 50–60% share and a high-margin razor-razor-blade business ...

We came across a bullish thesis on ResMed Inc. on Best Anchor Stocks’s Substack. In this article, we will summarize the bulls ...

By Siddhi Mahatole Jan 29 (Reuters) - Medical device maker ResMed on Thursday beat Wall Street estimates for second-quarter profit on the back of strong demand for its devices used to manage sleep ...

Resmed has beaten expectations with $2 billion in second-quarter revenue and says weight loss drugs are actually boosting ...

Q2 FY2026 earnings call recap: 11% revenue growth, margin expansion, AI innovation, and updated 62–63% guidance—read key takeaways now.

Sleep apnea can result in daytime fatigue and irritability. Obstructive Sleep Apnea, defined as having frequent episodes of ...

Resmed shares are down a bit today, even though second-quarter results came in ahead of the consensus forecast.

Masks and accessories were the standout growth category for Resmed in the second quarter of its fiscal year 2026, with the company reporting a 16% increase in revenue in the United States, Canada and ...

SAN DIEGO – Resmed reported revenue increased 11% to $1.4 billion for its second quarter of fiscal year 2026. Other financial results: Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 ...

Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps ...

(RMD) on Thursday reported fiscal second-quarter net income of $392.6 million. On a per-share basis, the San Diego-based company said it had net income ...